Quest Diagnostics Incorporated
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DGX research report →
Range $245 – $262
Price Chart
About the company
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients.
- CEO
- James E. Davis
- IPO
- 1996
- Employees
- 57,000
- HQ
- Secaucus, NJ, US
Get TickerSpark's AI analysis on DGX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.42B
- P/E
- 25.18
- Fwd P/E
- 22.82
- PEG
- 1.41
- P/S
- 2.38
- P/B
- 3.69
- EV/EBITDA
- 14.63
- Div Yield
- 1.32%
- Gross Margin
- 33.11%
- Op Margin
- 14.55%
- Net Margin
- 9.53%
- ROE
- 15.21%
- ROIC
- 8.54%
Latest fiscal year · YoY change
- Revenue
- $11.04B+11.8%
- Gross Profit
- $3.67B+13.0%
- Op Income
- $1.56B
- Net Income
- $992.00M+13.9%
- EPS
- $8.87+13.7%
- OCF Growth
- +41.4%
- FCF Growth
- +49.5%
- 52W High
- $263.19
- 52W Low
- $171.18
- 50D MA
- $243.26
- 200D MA
- $217.16
- Beta
- 0.55
- RSI (14)
- 61
- Avg Volume
- 1.03M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Quest Diagnostics posted a strong third quarter with 10% revenue growth and 15%+ adjusted EPS growth, and raised full-year guidance despite looming PAMA pressure.· October 22, 2026
- Consolidated revenue was $3.1 billion, up 10% year over year, with adjusted EPS of $3.00, up 15.4%.
- Organic revenue grew 10.1% and organic volume rose 14.4%, reflecting strength in physician, hospital, and consumer channels.
- Management raised and narrowed 2026 guidance for revenue and EPS after a strong quarter.
- Consumer health remained a standout, with growth expected to exceed 30% for the full year and a new Apple Health app offering set to launch later this year.
- PAMA remains the biggest medium-term overhang; Quest reiterated that 2027 cuts could hit revenues by about 1% and is pushing Congress for the RESULTS Act.
Quest reported third-quarter 2026 consolidated revenues of $3.1 billion, up 10% versus last year. Diagnostic Information Services revenues rose 10.2% year over year, and 10.1% organically. Total requisitions increased 14.5%, with organic volume up 14.4%. Reported operating income was $479 million, or 15.5% of revenue, versus $386 million, or 13.7% last year; adjusted operating income was $517 million, or 16.7% of revenue, versus $458 million, or 16.3% last year. Reported EPS was $2.78 versus $2.16, and adjusted EPS was $3.00 versus $2.60, up 15.4%. Cash from operations was $1.49 billion year to date versus $1.42 billion last year. For full-year 2026, Quest now expects revenue of $12.065 billion to $12.105 billion, reported EPS of $10.21 to $10.31, adjusted EPS of $11.25 to $11.35, cash from operations of about $1.9 billion, and capital expenditures of about $550 million. Management said operating margin should expand versus prior year, share count should be slightly below 2025, the adjusted tax rate should be consistent with 2025, and interest expense should be lower than 2025.
Jim Davis framed the quarter as evidence that Quest’s strategy is working across core and growth channels, emphasizing stronger clinical demand, consumer wellness growth, and productivity gains from automation and AI. He highlighted physician, hospital, and consumer momentum, plus expansions in kidney diagnostics, Alzheimer’s testing, and women’s health. His tone was confident and opportunistic, but he also spent substantial time on PAMA, arguing the CMS data collection process was flawed and pressing Congress to pass the bipartisan RESULTS Act.
Sam Samad focused on the financial outperformance and margin improvement. He cited 10% revenue growth, 14.5% requisition growth, reported operating margin of 15.5%, adjusted operating margin of 16.7%, and adjusted EPS growth of 15.4%, then said the company is raising full-year guidance to $12.065 billion-$12.105 billion of revenue and $11.25-$11.35 of adjusted EPS. He also flagged year-to-date cash from operations of $1.49 billion, capex of about $550 million for 2026, a $0.25 EPS impact from Project Nova with about 70% in the second half, and expected 2027 PAMA impact of about 1% of revenues, with some offset to be determined through budgeting.
Analysts focused heavily on PAMA, asking how much of the expected headwind could be offset, whether another delay is possible, and why the estimated impact had increased. Management said the 2027 PAMA hit is still roughly 1% of revenues, that it plans to offset part of it through efficiencies and budgeting, and that it will not cut growth-driving investments, front-line staffing, or lab operations. Questions also centered on consumer growth and the Apple Health partnership, with Quest saying the launch is still in beta and uptake is too early to forecast, though management believes the offering could be meaningful over time. Other Q&A topics included margin drivers, ACA exchange disenrollment, DSO increases, cybersecurity disclosure, and the growth opportunity in nephrology.
The quarter showed broad-based operational momentum, with strong growth across physician, hospital, and consumer channels and no sign of a slowdown in core utilization. Management is also seeing margin support from automation, AI, and the higher-density consumer business, while new initiatives like Apple Health, kidney diagnostics, and new Alzheimer’s biomarkers could extend growth into 2027.
The biggest risk discussed was PAMA, which could pressure 2027 revenue by about 1% and remains dependent on legislative action that is not yet secured. Management also said Project Nova will add expense in 2026 and beyond, and the company acknowledged that Corewell and Fresenius will no longer be a growth tailwind once they are lapped. Cybersecurity-related unauthorized access was disclosed, though management said it had not materially disrupted operations at this time.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.5%
- Shares Outstanding
- 110.02M
- Float Shares
- 109.49M
of shares held by institutions
1,128 13F filers
Buy/sell ratio 1.56. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for DGX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Carol Devine MillerHouse · WV01 | Sell | Mar 10, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Oct 30, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Buy | Oct 30, 25 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 30, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Apr 28, 25 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Jul 24, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Nov 3, 25 | Filing → |
| Carol Devine MillerHouse · WV01 | Sell | Mar 10, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jan 24, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 15, 24 | Filing → |
| Earl BlumenauerHouse · OR03 | Sell | Apr 4, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 14.39M | ▲ 140.45K |
| Blackrock, Inc. | 9.25M | ▼ 23.51K |
| Vanguard Capital Management LLC | 7.23M | ▼ 4.82K |
| Vanguard Portfolio Management LLC | 6.11M | ▼ 18.13K |
| State Street Corp | 5.56M | ▲ 40.98K |
| Price T Rowe Associates Inc | 5.02M | ▼ 423.98K |
| Boston Partners | 4.64M | ▼ 104.52K |
| Fmr LLC | 4.51M | ▲ 3.11M |
| Geode Capital Management, LLC | 3.16M | ▲ 26.96K |
| Jpmorgan Chase & Co | 2.89M | ▼ 632.40K |
| Morgan Stanley | 2.47M | ▲ 6.99K |
| Edgepoint Investment Group Inc. | 2.10M | ▼ 150.07K |
Held by 1,900 ETFs
Biggest fund positions in DGX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Deppe Michael J | other | 6,261 |
| Nov 13, 26 | Deppe Michael J | other | 5,515 |
| Nov 13, 26 | Deppe Michael J | sell | 5,515 |
| Nov 13, 26 | Deppe Michael J | other | 6,261 |
| Nov 13, 26 | Deppe Michael J | other | 5,515 |
| Nov 9, 26 | Plewman Patrick | other | 6,793 |
| Nov 9, 26 | Plewman Patrick | other | 4,274 |
| Nov 9, 26 | Plewman Patrick | sell | 6,793 |
| Nov 9, 26 | Plewman Patrick | sell | 650 |
| Nov 9, 26 | Plewman Patrick | other | 6,793 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DGX coverage
Recent articles, reports, and earnings notes.
No research on DGX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DGX report →Quest Diagnostics Stock Gains 49.3% YTD: What's Behind the Rally?
zacks.com · Nov 20
Quest Diagnostics Incorporated (DGX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 17
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
zacks.com · Nov 12
Quest Diagnostics Declares Quarterly Cash Dividend
prnewswire.com · Nov 10
Quest Diagnostics to Speak at the 9th Annual Evercore Healthcare Conference
prnewswire.com · Nov 9
Quest Diagnostics to Speak at the Jefferies Global Healthcare Conference in London
prnewswire.com · Nov 9
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
zacks.com · Oct 27
Riverwater Partners Sustainable Value Strategy Q3 2026 Portfolio Update
seekingalpha.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.